Clinical TrialsSearch results
Number of results: 314
Other
- A prospective,randomized,single-blind,comparative study of Inslow,palatinose-based liquid formula and Meibalance,standard balanced liquid formula,using viscera fat accumulation as a primary endpoint in adults patients with confirmed diagnosis of obesity and impaired glucose tolerance.
- Obesity and impaired glucose tolerance
- Meiji Dairies Corporation
- 2009-01-01
Other
- Relationship between the response to CPT-11/platimun regimen and BCRP DNA Metylation in patients with NSCLC recurrence after surgical resection.
- NSCLC
- Nagasaki Thoracic Oncology Group
- 2012-12-31
Other
- To evaluate the relationships between the serum concentration of EGFR-TKIs and the effects and toxicities of them
- NSCLC
- Nagasaki Thoracic Oncology Group
- 2013-12-31
Other
- A randomised crossover study comparing tafluprost and travoprost in subjects with normal tension glaucoma of pseudophakic eye
- Normal tension glaucoma of pseudophakic eye
- MIzoguchi Eye Clinic
- 2009-06-15
Other
- Ocular hypotensive effects of tafluprost and travoprost in normal tension glaucoma; open-label,multi center, cross-over study
- Normal Tension Glaucoma
- Mizoguchi Eye Clinic
- 2009-04-01
Other
- Feasibility study of adjuvant chemotherapy with S-1 in elderly patients with non-small-cell lung cancer
- non-small-cell lung cancer
- Lung Oncology Group in Kyushu, Japan (LOGIK)
- 2009-08-25
Other
- Randomiazed controlled trial comparing docetaxel-cisplatin combination with docetaxel alone in elderly patients with advanced non-small-cell lung cancer(JCOG0803/WJOG4307L)
- non-small-cell lung cancer
- Japan Clinical Oncology Group(JCOG)
- 2008-10-10
Other
- Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small sell lung carcinoma (NSCLC)
- Non-small sell lung carcinoma (NSCLC)
- The Tokyo cooperative oncology group
- 2006-01-23
Other
- Docetaxel(D) versus docetaxel plus gemcitabine(DG) for second-line treatment of non-small cell lung cancer (NSCLC) : Results of a JCOG randomized trial (JCOG0104)
- Non-small cell Lung Cancer
- Japan Clinical Oncology Group(JCOG)
- 2005-07-22
Other
- phase II study of Erlotinib for non-small cell lung cancer patients with EGFR mutation
- non-small cell lung cancer
- Nagasaki Thoracic Oncology Group
- 2009-04-04